RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:98845

Classic Hodgkin lymphoma, lymphocyte-rich type

high confidenceSubtype of disorder

Publications

256

63.4th percentile

Trials

4

Interventional, condition-specific

Researchers

1,310

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (13)

Hodgkin lymphoma, lymphocyte-rich · Hodgkin's disease, lymphocyte predominance [obs] · LRCHL · classic Hodgkin lymphoma, lymphocyte-rich type · lymphocyte rich Hodgkin lymphoma · lymphocyte rich Hodgkin's disease · lymphocyte rich Hodgkin's lymphoma · lymphocyte rich classical Hodgkin lymphoma · lymphocyte rich classical Hodgkin's disease · lymphocyte rich classical Hodgkin's lymphoma · lymphocyte-rich Classic Hodgkin lymphoma · lymphocyte-rich classical Hodgkin lymphoma · lymphocyte-rich classical Hodgkin's lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    256 matched papers (148 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    4 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

256

256 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

256 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

148 in the last 10 years · high confidence · 63.4th percentile (publications denominator)

Phrase hits: 256 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,310

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Jaffe ES12 papers · 2024

    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. elainejaffe@nih.gov

    Papers in Europe PMC
  2. 02
    Nakamura S7 papers · 2023

    Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.

    Papers in Europe PMC
  3. 03
    Satou A6 papers · 2023

    Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

    Papers in Europe PMC
  4. 04
    Takahara T5 papers · 2023

    Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

    Papers in Europe PMC
  5. 05
    Engert A4 papers · 2019

    First Department of Internal Medicine and German Hodgkin Study Group, University Hospital of Cologne, Germany.

    Papers in Europe PMC
  6. 06
    Harris NL4 papers · 2016

    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Warren Building 2nd floor, Boston, MA 02114 USA.

    Papers in Europe PMC
  7. 07
    Pileri SA4 papers · 2022

    Haematopathology Division, European Institute of Oncology-IEO IRCCS Milan, 20141 Milan, Italy.

    Papers in Europe PMC
  8. 08
    Piris MA4 papers · 2023

    Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.

    Papers in Europe PMC
  9. 09
    Swerdlow SH4 papers · 2022

    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA.

    Papers in Europe PMC
  10. 10
    Ascani S3 papers · 2021

    Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

4

interventional trials for this specific condition

4 interventional trials matched this specific condition name; none in our sample are currently recruiting. 43 trials are registered for classic Hodgkin lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

4 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 88.1th percentile).

high confidence · 88.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

4 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Broader category: classic Hodgkin lymphoma

43

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 66 · after dedupe 66 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 66 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (66)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Classic Hodgkin lymphoma, lymphocyte-rich type — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Classic Hodgkin lymphoma, lymphocyte-rich type" OR "Hodgkin lymphoma, lymphocyte-rich" OR "Hodgkin's disease, lymphocyte predominance [obs]" OR "LRCHL" OR "lymphocyte rich Hodgkin lymphoma" OR "lymphocyte rich Hodgkin's disease" OR "lymphocyte rich Hodgkin's lymphoma" OR "lymphocyte rich classical Hodgkin lymphoma" OR "lymphocyte rich classical Hodgkin's disease" OR "lymphocyte rich classical Hodgkin's lymphoma" OR "lymphocyte-rich Classic Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin's lymphoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic Hodgkin lymphoma, lymphocyte-rich type" OR "Hodgkin lymphoma, lymphocyte-rich" OR "Hodgkin's disease, lymphocyte predominance [obs]" OR "LRCHL" OR "lymphocyte rich Hodgkin lymphoma" OR "lymphocyte rich Hodgkin's disease" OR "lymphocyte rich Hodgkin's lymphoma" OR "lymphocyte rich classical Hodgkin lymphoma" OR "lymphocyte rich classical Hodgkin's disease" OR "lymphocyte rich classical Hodgkin's lymphoma" OR "lymphocyte-rich Classic Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin lymphoma" OR "lymphocyte-rich classical Hodgkin's lymphoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 4 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"classic Hodgkin lymphoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T05:34:37.492Z